to the European MCL Network

The European MCL Network consists of 15 national lymphoma study groups supplemented by experts in histopathology and molecular genetics. Selection of individual partners was exclusively based on scientific excellence, profound clinical experience of MCL treatment, broad knowledge of the underlying molecular pathogenesis and outstanding methodological expertise.


Participating clinical study groups and national representative:

  • Australasian lymphoma study group (J. Seymour, Melbourne/Australia)
  • CLSG (M. Trneny, Prag/Czech Republic)
  • Croatian Study group (I. Aurer, Zagreb/Croatia)
  • FIL (Italian Intergroup) (M. Ladetto, C. Visco, Torino/Italy)
  • GELTAMO (E Giné, A Marin, Barcelona/Spain)
  • GLA (M. Dreyling, Munich/Germany)
  • HOVON (J. Doorduijn, Rotterdam/Netherlands)
  • Israelian Study group (O. Shpilberg, Petah-Tiqva/Israel)
  • LYSA (O. Hermine, V. Ribrag, St. Le Gouill, Paris/France)
  • NCIC (J. Kuruvilla, Toronto/Canada)
  • NCRI (S. Rule, Plymouth/United Kingdom)
  • Nordic Lymphoma Group (M. Jerkeman, Copenhagen/Denmark)
  • PLRG (J. Walewski, Warzawa/Poland)
  • Portuguese LSG (M. Gomes da Silva, Lisboa/Portugal)
  • SAKK (M. Fehr, St.Gallen/Switzerland)
  • Lymphoma Forum of Ireland (E. Vandenberghe)


During the last decade, our European consortium has successfully completed the largest phase III trials in MCL worldwide with a current annual recruitment of almost 200 patients per year in our first line studies. Detailed results have been presented at the last ASH and Lugano conferences.

Corporate Partners - Individual Sponsors
Mon, 6th February 2023
Czernecki-Donelly Award 2023
of the European MCL Network
more news